Covidien vascular plant to close
A Covidien plant in Argyle, N.Y., specializing in producing vascular products, as well as some respiratory and monitoring solution products, will close its doors in 12 to 18 months and move production to locations outside the country, according to a spokesperson from the company.
“After a lengthy business and financial review, we decided to close the plant to achieve operational and strategic growth,” said company spokesperson Rachel Bloom-Baglin, adding that the closure is part of a 2008 global restructuring plan.
The 200 employees at the plant will have the opportunity to apply for other jobs within the company at different locations, and those who are eligible will receive outplacement services and severance packages, Bloom-Baglin noted.
Asked if any other closures can be expected, Bloom-Baglin said the company will continue “reviewing our global operation and our commercial business. It’s ongoing.”
Covidien's vascular line includes its cardiothoracic, dialysis and vascular compression units.
“After a lengthy business and financial review, we decided to close the plant to achieve operational and strategic growth,” said company spokesperson Rachel Bloom-Baglin, adding that the closure is part of a 2008 global restructuring plan.
The 200 employees at the plant will have the opportunity to apply for other jobs within the company at different locations, and those who are eligible will receive outplacement services and severance packages, Bloom-Baglin noted.
Asked if any other closures can be expected, Bloom-Baglin said the company will continue “reviewing our global operation and our commercial business. It’s ongoing.”
Covidien's vascular line includes its cardiothoracic, dialysis and vascular compression units.